Pharmacological neuroprotection in stroke in clinical practice: new perspectives

Close metadata

Despite recent advances in acute stroke care, clinical armamentarium against stroke remains limited. Furthermore, highly effective approaches to stroke treatment, such as systemic reperfusion and mechanical thrombectomy, cannot be performed in the majority of patients. Neuroprotective strategies, i.e. prevention of irreversible cell damage due to the ischemia, may improve stroke outcomes. However, only few pharmacological agents demonstrated clinical efficacy. Citicoline is an endogenous mononucleotide with neuroprotective effect and established clinical safety and tolerability, which effectiveness in acute stroke was studied in several large, well-controlled trials. Recent meta-analysis confirmed benefit of citicoline treatment in terms of increase of chance for better recovery of functional independence compared to placebo. Maximal effect of citicoline is seen when it is administered as soon as possible after stroke onset in patients who are not eligible for reperfusion therapy.

Keywords:

acute stroke

neuroprotection

citicoline

Authors:

Sergeev D.V.

Research Center of Neurology, Moscow, Russia

Domashenko M.A.

FGBU "Nauchnyĭ tsentr nevrologii" RAN, Moskva

Piradov M.A.

Federal State budgetary scientific Institution «Research Centre of Neurology», Moscow

SPIN RSCI: 2860-1689
Scopus AuthorID: 7003731802
ResearcherID: B-4407-2012
ORCID: 0000-0002-6338-0392

List of references:

Hankey G. Stroke. The Lancet. 2016. doi:10.1016/s0140-6736(16)30962-x
Maksimova MYu, Sineva NA, Vodop'yanov NP, Suanova ET, Suslina ZA, Piradov MA, Domashenko MA. Stroke: 15 years later. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(11):5-13. (In Russ.).
Jauch E, Saver J, Adams H, Bruno A, Connors J, Demaerschalk B, Khatri P, McMullan P, Qureshi A, Rosenfield K, Scott P, Summers D, Wang D, Wintermark M, Yonas H. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947. doi:10.1161/str.0b013e318284056a
Powers W, Derdeyn C, Biller J, Coffey C, Hoh B, Jauch E, Johnston K, Johnston S, Khalessi A, Kidwell C, Meschia J, Ovbiagele B, Yavagal D. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment. Stroke. 2015;46(10):3020-3035. doi:10.1161/str.0000000000000074
Goyal M, Yu A, Menon B, Dippel D, Hacke W, Davis S, Fisher M, Yavagal D, Turjman F, Ross J, Yoshimura S, Miao Z, Bhatia R, Almekhlafi M, Murayama Y, Sohn S, Saver J, Demchuk A, Hill M. Endovascular Therapy in Acute Ischemic Stroke. Stroke. 2016;47(2):548-553. doi:10.1161/strokeaha.115.011426
Feigin V, Forouzanfar M, Krishnamurthi R, Mensah G, Connor M, Bennett D, Moran A, Sacco R, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes C, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990—2010: findings from the Global Burden of Disease Study 2010. The Lancet. 2014;383(9913):245-255. doi:10.1016/s0140-6736(13)61953-4
Feigin V, Krishnamurthi R, Parmar P, Norrving B, Mensah G, Bennett D, Barker-Collo S, Moran A, Sacco R, Truelsen T, Davis S, Pandian J, Naghavi M, Forouzanfar M, Nguyen G, Johnson C, Vos T, Meretoja A, Murray C, Roth G. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990—2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161-176. doi:10.1159/000441085
Ginsberg M. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology. 2008;55(3):363-389. doi:10.1016/j.neuropharm.2007.12.007
Ginsberg M. Expanding the concept of neuroprotection for acute ischemic stroke: The pivotal roles of reperfusion and the collateral circulation. Progress in Neurobiology. 2016;145-146:46-77. doi:10.1016/j.pneurobio.2016.09.002
Grupke S, Hall J, Dobbs M, Bix G, Fraser J. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview. Clinical Neurology and Neurosurgery. 2015;129:1-9. doi:10.1016/j.clineuro.2014.11.013
Piradov M.A., Tanashyan M.M., Domashenko M.A., Sergeev D.V., Maksimova M.Yu. Neiroprotektsiya pri tserebrovaskulyarnykh zabolevaniyakh: poisk zhizni na marse ili perspektivnoe napravlenie lecheniya? Chast' 1. Ostrye narusheniya mozgovogo krovoobrashcheniya. Annaly klinicheskoi i eksperimental'noi nevrologii. 2015;9(1):41-50.
Chamorro Á, Amaro S, Castellanos M, Segura T, Arenillas J, Martí-Fábregas J, Gállego J, Krupinski J, Gomis M, Cánovas D, Carné X, Deulofeu R, Román LS, Oleaga L, Torres F, Planas AM. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. The Lancet Neurology. 2014;13(5):453-460. doi:10.1016/s1474-4422(14)70054-7
Shuaib A, Lees K, Lyden P, Grotta J, Davalos A, Davis S, Diener H, Ashwood T, Wasiewski W, Emeribe U. NXY-059 for the Treatment of Acute Ischemic Stroke. New England Journal of Medicine. 2007;357(6):562-571. doi:10.1056/nejmoa070240
De Deyn P, De Reuck J, Deberdt W, Vlietinck R, Orgogozo J. Treatment of Acute Ischemic Stroke With Piracetam. Stroke. 1997;28(12):2347-2352. doi:10.1161/01.str.28.12.2347
Ginsberg M, Palesch Y, Hill M, Martin R, Moy C, Barsan W, Waldman B, Tamariz D, Ryckborst K. High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial. The Lancet Neurology. 2013;12(11):1049-1058. doi:10.1016/s1474-4422(13)70223-0
Saver J, Starkman S, Eckstein M, Stratton S, Pratt F, Hamilton S, Conwit R, Liebeskind D, Sung G, Kramer I, Moreau G, Goldweber R, Sanossian N. Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke. New England Journal of Medicine. 2015;372(6):528-536. doi:10.1056/nejmoa1408827
Domashenko MA, Piradov MA, Sergeev DV, Maksimova MYu. Citicoline in acute stroke: from evidences to clinical practice. Russkii meditsinskii zhurnal. 2014;22(22):1609-1612. (In Russ.).
Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Vallejo-Cremades M, Álvarez-Grech J, Expósito-Alcaide M, Díez-Tejedor E. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochemistry International. 2012;60(3):310-317. doi:10.1016/j.neuint.2011.12.015
Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Revista de Neurología. 2011;52(suppl 2):1-62.
Álvarez-Sabín J, Román G. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sciences. 2013;3(3):1395-3414. doi:10.3390/brainsci3031395
Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods and Findings in Experimental and Clinical Pharmacology. 2006;28(suppl B):1-56.
Schäbitz W, Weber J, Takano K, Sandage B, Locke K, Fisher M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. Journal of the Neurological Sciences. 1996;138(1-2):21-25. doi:10.1016/0022-510x(95)00341-x
Andersen M, Overgaard K, Meden P, Boysen G. Effects of Citicoline Combined With Thrombolytic Therapy in a Rat Embolic Stroke Model. Stroke. 1999;30(7):1464-1471. doi:10.1161/01.str.30.7.1464
Secades J, Frontera G. CDP-choline: pharmacological and clinical review. Methods and Findings in Experimental and Clinical Pharmacology. 1995;17(suppl B):1-54.
Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, Fujishima M, Sakuma A. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke. 1988;19(2):211-216. doi:10.1161/01.str.19.2.211
Clark W, Warach S, Pettigrew L, Gammans R, Sabounjian L. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 1997;49(3):671-678. doi:10.1212/wnl.49.3.671
Clark W, Wechsler L, Sabounjian L, Schwiderski U. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001;57(9):1595-1602. doi:10.1212/wnl.57.9.1595
Clark W, Williams B, Selzer K, Zweifler R, Sabounjian L, Gammans R. A Randomized Efficacy Trial of Citicoline in Patients With Acute Ischemic Stroke. Stroke. 1999;30(12):2592-2597. doi:10.1161/01.str.30.12.2592
Warach S, Creed Pettigrew L, Dashe J, Pullicino P, Lefkowitz D, Sabounjian L, Harnett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology. 2000;48(5):713-722. doi:10.1002/1531-8249(200011)48:5<713::aid-ana4>3.0.co;2-#
Piradov MA, Sergeev DV, Krotenkova MV. Citicoline (Ceraxon) in acute stroke: assessment of clinical efficacy and effects on cerebral perfusion. Annaly klinicheskoi i eksperimental'noi nevrologii. 2012;6(3):31-36. (In Russ.).
Davalos A, Castillo J, Alvarez-Sabin J, Secades J, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark W, Lozano R. Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials. Stroke. 2002;33(12):2850-2857. doi:10.1161/01.str.0000038691.03334.71
Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz V, Masjuan J, Cobo E, Secades J. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). The Lancet. 2012;380(9839):349-357. doi:10.1016/s0140-6736(12)60813-7
Secades J, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. Journal of Stroke and Cerebrovascular Diseases. 2016;25(8):1984-1996. doi:10.1016/j.jstrokecerebrovasdis.2016.04.010
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org
Higgins J. Measuring inconsistency in meta-analyses. British Medical Journal. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557
Nuesch E, Trelle S, Reichenbach S, Rutjes A, Tschannen B, Altman D, Egger M, Juni P. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. British Medical Journal. 2010;341(jul16 1):3515-3515. doi:10.1136/bmj.c3515

Close metadata